Original Source(s)
Related Content
Trial Exclusions May Skew RA Drug Comparisons
Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.
June 12, 2026
-
5 min
Emergency diagnosis may flag poor outcomes beyond cancer
Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.
August 31, 2026
-
4 min
Joint Site May Influence RA Treatment Response
A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.
July 15, 2026
-
4 min
